Monopar Announces Initial Data For First Patient Dosed In Radiopharma Phase 1 Clinical Trial If MNPR-101-Zr; Says MNPR-101-Zr Was Well-Tolerated With No Serious Adverse Reactions Reported Through The Last Imaging Timepoint And Corresponding Initial Safety Review
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics announced initial data for the first patient dosed in their Phase 1 clinical trial of MNPR-101-Zr, a radiopharmaceutical. The treatment was well-tolerated with no serious adverse reactions reported through the last imaging timepoint and initial safety review.
August 14, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics announced positive initial data for their Phase 1 clinical trial of MNPR-101-Zr, showing the treatment was well-tolerated with no serious adverse reactions.
The positive initial data and absence of serious adverse reactions in the Phase 1 trial of MNPR-101-Zr are likely to boost investor confidence in Monopar Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100